Free Trial

Trevena (TRVN) Competitors

Trevena logo
$0.97 +0.06 (+6.59%)
As of 02:23 PM Eastern

TRVN vs. TTNP, PLRZ, EVOK, LIPO, DRMA, VIVS, CMND, CANF, ARTL, and CERO

Should you be buying Trevena stock or one of its competitors? The main competitors of Trevena include Titan Pharmaceuticals (TTNP), Polyrizon (PLRZ), Evoke Pharma (EVOK), Lipella Pharmaceuticals (LIPO), Dermata Therapeutics (DRMA), VivoSim Labs (VIVS), Clearmind Medicine (CMND), Can-Fite BioPharma (CANF), Artelo Biosciences (ARTL), and CERo Therapeutics (CERO). These companies are all part of the "pharmaceutical products" industry.

Trevena vs. Its Competitors

Titan Pharmaceuticals (NASDAQ:TTNP) and Trevena (NASDAQ:TRVN) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, earnings, media sentiment, profitability, analyst recommendations, institutional ownership, valuation and dividends.

Trevena has a consensus target price of $5.00, indicating a potential upside of 415.46%. Given Trevena's stronger consensus rating and higher possible upside, analysts plainly believe Trevena is more favorable than Titan Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Titan Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Trevena
0 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00

In the previous week, Titan Pharmaceuticals and Titan Pharmaceuticals both had 1 articles in the media. Titan Pharmaceuticals' average media sentiment score of 0.00 equaled Trevena'saverage media sentiment score.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Titan Pharmaceuticals
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Trevena
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Trevena's return on equity of 0.00% beat Titan Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Titan PharmaceuticalsN/A -145.92% -129.20%
Trevena N/A N/A -119.55%

Titan Pharmaceuticals has a beta of 1.27, indicating that its share price is 27% more volatile than the S&P 500. Comparatively, Trevena has a beta of 0.61, indicating that its share price is 39% less volatile than the S&P 500.

Titan Pharmaceuticals has higher earnings, but lower revenue than Trevena. Titan Pharmaceuticals is trading at a lower price-to-earnings ratio than Trevena, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Titan Pharmaceuticals$180K22.37-$4.71M-$4.59-0.96
Trevena$443K2.10-$40.29M-$47.04-0.02

31.5% of Titan Pharmaceuticals shares are owned by institutional investors. Comparatively, 13.6% of Trevena shares are owned by institutional investors. 0.7% of Titan Pharmaceuticals shares are owned by insiders. Comparatively, 2.7% of Trevena shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Trevena beats Titan Pharmaceuticals on 7 of the 12 factors compared between the two stocks.

Get Trevena News Delivered to You Automatically

Sign up to receive the latest news and ratings for TRVN and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TRVN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

TRVN vs. The Competition

MetricTrevenaPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$930K$790.52M$5.54B$8.99B
Dividend YieldN/A4.84%5.25%4.04%
P/E Ratio-0.021.3027.5520.17
Price / Sales2.10225.41432.66125.29
Price / CashN/A23.4436.8257.86
Price / Book-0.096.138.105.60
Net Income-$40.29M-$27.58M$3.17B$248.58M
7 Day Performance-11.82%1.19%4.21%5.33%
1 Month Performance-4.90%8.40%3.85%7.26%
1 Year Performance-82.04%7.15%34.49%21.87%

Trevena Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
TRVN
Trevena
1.5947 of 5 stars
$0.97
+6.6%
$5.00
+415.5%
-83.0%$930K$443K-0.0240News Coverage
Gap Down
TTNP
Titan Pharmaceuticals
0.0935 of 5 stars
$4.20
-4.5%
N/A-13.6%$4.02M$180K-0.9210
PLRZ
Polyrizon
N/A$0.74
0.0%
N/AN/A$3.94MN/A0.00N/A
EVOK
Evoke Pharma
0.3417 of 5 stars
$2.60
-1.1%
N/A-59.0%$3.92M$10.25M-0.914News Coverage
Gap Up
LIPO
Lipella Pharmaceuticals
1.5135 of 5 stars
$0.87
-3.6%
N/A-77.5%$3.88M$536.36K-0.214
DRMA
Dermata Therapeutics
1.9991 of 5 stars
$0.59
-3.2%
$3.00
+412.8%
-72.7%$3.85MN/A-0.048News Coverage
Positive News
Gap Up
VIVS
VivoSim Labs
N/A$1.47
flat
N/AN/A$3.82M$140K-0.1420Positive News
CMND
Clearmind Medicine
0.6373 of 5 stars
$0.90
+1.2%
N/A-37.6%$3.79MN/A-0.82N/A
CANF
Can-Fite BioPharma
3.2727 of 5 stars
$1.05
+1.0%
$14.00
+1,233.3%
-60.1%$3.72M$674K-0.598
ARTL
Artelo Biosciences
3.1455 of 5 stars
$13.27
+95.4%
$33.00
+148.7%
+100.7%$3.71MN/A-0.745News Coverage
Analyst Upgrade
Gap Up
High Trading Volume
CERO
CERo Therapeutics
3.6529 of 5 stars
$9.63
+0.8%
$45.00
+367.3%
-97.9%$3.69MN/A0.008Gap Up

Related Companies and Tools


This page (NASDAQ:TRVN) was last updated on 7/9/2025 by MarketBeat.com Staff
From Our Partners